|
Re: Roth research report
|
8
|
Resverlogix Corp.
|
Oct 31, 2018 10:20PM
|
|
The scariest thing for a clinical trial......
|
2
|
Resverlogix Corp.
|
Oct 31, 2018 07:24PM
|
|
Roth coverage
|
4
|
Resverlogix Corp.
|
Oct 29, 2018 11:59AM
|
|
Re: First xB3 platform technology licensing agreement with Prothena; USD$1M upfront+potential up to USD$33M in payments
|
3
|
BIOASIS TECHNOLOGIES INC
|
Oct 29, 2018 08:40AM
|
|
Re: ESPR results
|
9
|
Resverlogix Corp.
|
Oct 28, 2018 11:28PM
|
|
BIO Europe
|
3
|
Zenith Epigenetics
|
Oct 28, 2018 08:34AM
|
|
Re: Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences
|
2
|
Resverlogix Corp.
|
Oct 28, 2018 08:33AM
|
|
Re: Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences
|
4
|
Resverlogix Corp.
|
Oct 26, 2018 01:36PM
|
|
Re: Resverlogix H2 2018 events
|
5
|
Resverlogix Corp.
|
Oct 24, 2018 01:19PM
|
|
Re: Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences
|
6
|
Resverlogix Corp.
|
Oct 22, 2018 10:28AM
|
|
Re: Endocyte Valuation
|
2
|
Zenith Epigenetics
|
Oct 18, 2018 02:54PM
|
|
Re: Endocyte Valuation
|
2
|
Zenith Epigenetics
|
Oct 18, 2018 02:35PM
|
|
CANTOS good, but FDA not on board with sub-group analysis
|
6
|
Resverlogix Corp.
|
Oct 18, 2018 02:03PM
|
|
Re: Must be a dilutive financing in the works...
|
4
|
Resverlogix Corp.
|
Oct 18, 2018 12:35PM
|
|
Re: Must be a dilutive financing in the works...
|
1
|
Resverlogix Corp.
|
Oct 18, 2018 11:32AM
|
|
Re: Must be a dilutive financing in the works...
|
2
|
Resverlogix Corp.
|
Oct 18, 2018 09:53AM
|
|
Re: Resverlogix October 2018 events
|
4
|
Resverlogix Corp.
|
Oct 18, 2018 09:50AM
|
|
Re: Resverlogix October 2018 events
|
6
|
Resverlogix Corp.
|
Oct 18, 2018 08:46AM
|
|
Re: Zenith presents at BIO Investor Forum Oct 17th
|
4
|
Zenith Epigenetics
|
Oct 17, 2018 10:19PM
|
|
Re: Resverlogix October 2018 events
|
3
|
Resverlogix Corp.
|
Oct 17, 2018 10:18PM
|
